<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04571619</url>
  </required_header>
  <id_info>
    <org_study_id>HOPE</org_study_id>
    <secondary_id>U01DK123813</secondary_id>
    <nct_id>NCT04571619</nct_id>
  </id_info>
  <brief_title>HOPE Consortium Trial to Reduce Pain and Opioid Use in Hemodialysis</brief_title>
  <acronym>HOPE</acronym>
  <official_title>A Randomized Clinical Trial to Evaluate Non-Pharmacologic and Pharmacologic Approaches for Reducing Pain and Opioid Use Among Patients Treated With Maintenance Hemodialysis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hennepin Health Care</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>New York University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Illinois at Chicago</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Washington</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of New Mexico</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Rogosin Institute</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West Virginia University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Yale University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Durham VA Health Care System</agency>
      <agency_class>U.S. Fed</agency_class>
    </collaborator>
    <collaborator>
      <agency>VA Portland Healthcare System</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>West Haven VA Medical Center</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      HOPE is a randomized clinical trial that will evaluate approaches to reducing pain and opioid&#xD;
      use among patients with chronic pain who are receiving maintenance hemodialysis for end-stage&#xD;
      renal disease. The hypothesis is that pain coping skills training will be effective at&#xD;
      reducing pain and opioid use, and that buprenorphine will be acceptable and tolerable as an&#xD;
      approach to managing physical dependence on opioids in this patient population.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 3, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">February 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Sequential, multiple-assignment randomization</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain interference</measure>
    <time_frame>The primary outcome of pain interference will be ascertained at Week 12 coinciding with the end of the PCST weekly coaching sessions.</time_frame>
    <description>Pain interference as measured by the Brief Pain Index (BPI) Interference Scale. This is typically scored as the mean of the seven items. Lowest score - 0; Highest score - 10. A higher score is worse.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Pain intensity as measured by the Brief Pain Index (BPI) Severity Scale. Lowest score - 0; Highest score - 40. A higher score is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain catastrophizing</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Pain catastrophizing will be measured using the Pain Catastrophizing Scale (PCS) Short Form (SF) 6. Lowest score - 0; Highest score - 24. A higher score is worse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Opioid use</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of falls</measure>
    <time_frame>Throughout the 36-week follow-up</time_frame>
    <description>Event rate; # per patient year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of hospitalizations</measure>
    <time_frame>Throughout the 36-week follow-up</time_frame>
    <description>Event rate; # per patient year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death</measure>
    <time_frame>Throughout the 36-week follow-up</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Buprenorphine acceptability</measure>
    <time_frame>Week 36</time_frame>
    <description>The proportion of participants who initiate buprenorphine from among those randomized to the Buprenorphine group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Buprenorphine tolerability</measure>
    <time_frame>Week 36</time_frame>
    <description>The proportion of patients who do not discontinue buprenorphine due to adverse effects or intolerance.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Sense of Quality of Life</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Quality of life will be measured using the Single-Item QOL Scale (SIS) from McGill Quality of Life (MQOL) questionnaire. Lowest score - 0; highest score - 10; Higher score equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physical Functioning</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Physical functioning will be measured using the Patient-Reported Outcomes Measurement Information System (PROMIS) Physical Functioning Short Form (SF)-6b questionnaire. Lowest score - 6; Highest score - 30; Higher score equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Depression</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Depression will be measured using the Patient Health Questionnaire (PHQ)-9. Lowest score - 0; Highest score - 27; Lower score equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anxiety</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Anxiety will be measured using the Generalized Anxiety Disorder (GAD)-7 questionnaire. Lowest score - 0; Highest score - 21; Lower score equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Coping</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Coping will be measured using the 1-Item Coping Strategies Questionnaire (CSQ). Lowest score - 0; Highest score - 6; Lower score equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sleep Quality</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Sleep quality will be measure using the PROMIS Sleep Disturbance Short Form (SF) 6a and the Sleep Duration Question.&#xD;
PROMIS Sleep Disturbance SF 6a: Lowest score - 6; Highest score - 30; Lower score equals better outcome.&#xD;
Sleep Duration Question: Reported in hours and minutes of sleep; Higher number equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fatigue</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Fatigue will be measured using the PROMIS Fatigue Short Form (SF) 6a. Lowest score - 6; Highest score - 30; Lower score equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with Treatment</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Satisfaction will be measured using the Patient Global Impression of Change (PGIC). Lowest score - 1; Highest score - 7; Lower score equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Social Support</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Social support will be measured using the Multidimensional Scale of Perceived Social Support (MSPSS). Lowest score - 7; Highest score - 7; Higher score equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Family Intrusion</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Family intrusion will be measured using the PROMIS Satisfaction with Social Roles and Activities. Lowest score - 8; Highest score - 40; Higher score equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Self-Efficacy</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Self-efficacy will be measured using the PROMIS Self-Efficacy for Managing Chronic Conditions - Managing Symptoms - Short Form 8A and the Single item targeting self-efficacy for pain. PROMIS Self-Efficacy for Managing Chronic Conditions - Managing Symptoms - Short Form 8A: Lowest score - 8; Highest score - 40; Higher score equals better outcome.&#xD;
Single item targeting self-efficacy for pain: Lowest score - 0; Highest score - 100; Higher score equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Other Symptoms</measure>
    <time_frame>Weeks 12, 24, and 36</time_frame>
    <description>Other symptoms will be measured using the Dialysis Symptom Index (DSI). Lowest score - 0; Highest score - 150; Lower score equals better outcome.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Discrimination</measure>
    <time_frame>Week 36</time_frame>
    <description>Discrimination will be measured using the Everyday Discrimination Scale Short Version (EDS-S). Lowest score - 0; Highest score - 5; Lower score equals better outcome.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">640</enrollment>
  <condition>End Stage Renal Disease</condition>
  <condition>Chronic Pain</condition>
  <condition>Opioid Dependence</condition>
  <arm_group>
    <arm_group_label>Pain Coping Skills Training</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Usual Care</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Buprenorphine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>No Buprenorphine</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Pain Coping Skills Training (PCST)</intervention_name>
    <description>The PCST intervention will focus primarily on reducing pain interference in daily activities and improving pain self-management skills. For participants with recent or current opioid use, the PCST intervention will include motivational interviewing aimed at reducing opioid use. During Weeks 1 - 12 the PCST will be delivered by coaches via telehealth (video). During Weeks 13 - 24, the Interactive Voice Response (IVR) will be delivered via telephone. The telehealth component will consist of weekly sessions, each lasting 45-50 minutes. The IVR content, intended to enhance and sustain the effects of the coach-led session, will be delivered with daily telephone interactions, each lasting approximately 5 minutes. Both components of the intervention will be available in English and Spanish.</description>
    <arm_group_label>Pain Coping Skills Training</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Buprenorphine</intervention_name>
    <description>At Week 24, participants who meet the eligibility criteria for the buprenorphine intervention will be randomly assigned, with equal likelihood, to Buprenorphine or No Buprenorphine. Participants randomized to Buprenorphine will be provided with individualized buprenorphine treatment recommendations and encouraged to switch from their full agonist opioid medication to buprenorphine. Individualized buprenorphine treatment recommendations will be made by the study buprenorphine physician based on current opioid use and other relevant factors. Participants randomized to No Buprenorphine will continue to be followed without a pharmacologic study intervention.</description>
    <arm_group_label>Buprenorphine</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Age ≥ 18 years&#xD;
&#xD;
          2. Undergoing in-center maintenance hemodialysis for ≥90 days&#xD;
&#xD;
          3. English- or Spanish-speaking&#xD;
&#xD;
          4. Chronic pain defined as a response of &quot;Most days&quot; or &quot;Every day&quot; to the following&#xD;
             question: &quot;In the past 3 months, how often have you had pain?&quot; Answer options: Never,&#xD;
             Some days, Most days, Every day&#xD;
&#xD;
          5. Current Pain, Enjoyment of Life and General Activity Scale (PEG) score ≥ 4&#xD;
&#xD;
          6. Willing to provide informed consent&#xD;
&#xD;
          7. Willing to allow research team to obtain opioid pharmacy refill data&#xD;
&#xD;
          8. Willing to allow research team to contact and work with their opioid prescriber&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Current opioid use disorder&#xD;
&#xD;
          2. Current use of heroin&#xD;
&#xD;
          3. Current non-opioid substance use disorder with the exception of tobacco use disorder&#xD;
&#xD;
          4. Current use of methadone, buprenorphine, or naltrexone for opioid use disorder&#xD;
&#xD;
          5. Current receipt of hospice care&#xD;
&#xD;
          6. Cognitive impairment that, in the judgement of the research team, precludes trial&#xD;
             participation&#xD;
&#xD;
          7. Active suicidal intent&#xD;
&#xD;
          8. Unstable bipolar disorder, schizophrenia, post-traumatic stress disorder, or other&#xD;
             psychotic disorder&#xD;
&#xD;
          9. Life expectancy &lt; 6 months&#xD;
&#xD;
         10. Expected to receive a kidney transplant, transfer to another dialysis facility, or&#xD;
             transition to home dialysis within 6 months&#xD;
&#xD;
         11. Current incarceration&#xD;
&#xD;
         12. Any other condition that the investigator considers precludes participation in the&#xD;
             clinical trial&#xD;
&#xD;
        Subgroup with Current or Recent Opioid Use During eligibility screening all potential&#xD;
        participants will have opioid use ascertained using the timeline follow back approach. The&#xD;
        trial will enroll at least 300 participants (among the 640 total study participants) with&#xD;
        current or recent opioid use defined as patient-reported prescription opioid use during at&#xD;
        least 3 of the past 6 months. The number of participants in the opioid use subgroup will be&#xD;
        monitored throughout the trial enrollment period. If the rate of enrollment into the opioid&#xD;
        use subgroup is lower than targeted, trial enrollment will be restricted to individuals&#xD;
        meeting the opioid use criteria as long as necessary to ensure that the total enrollment&#xD;
        target for the trial is not met without reaching the opioid use subgroup target.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Laura Dember, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Natalie Kuzla, MA</last_name>
    <phone>2155732935</phone>
    <email>nkuzla@pennmedicine.upenn.edu</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Leah Bernardo</last_name>
    <phone>2157464755</phone>
    <email>lleah@pennmedicine.upenn.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>West Haven VA Healthcare System</name>
      <address>
        <city>West Haven</city>
        <state>Connecticut</state>
        <zip>06516</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Svetlana Vassilieva</last_name>
      <email>Svetlana.Vassilieva@va.gov</email>
    </contact>
    <investigator>
      <last_name>William Becker, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Illinois at Chicago</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60612</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheryl Gilmartin</last_name>
      <email>cher.gilmart@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Michael Fischer, MD, MSPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shananssa Percy</last_name>
      <email>spercy@partners.org</email>
    </contact>
    <investigator>
      <last_name>Sahir Kalim, MD,MMSc</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hennepin County Medical Center</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55415</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Ursula Munet</last_name>
      <email>UMunet@BermanCenter.org</email>
    </contact>
    <investigator>
      <last_name>Kirsten Johansen, MD, FASN</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of New Mexico</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87131</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Tammy Seaman</last_name>
      <email>TDSeaman@salud.unm.edu</email>
    </contact>
    <investigator>
      <last_name>Mark Unruh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>New York University</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sobaata Chaudry</last_name>
      <email>sobaata.chaudry@nuylangone.org</email>
    </contact>
    <investigator>
      <last_name>David Charytan, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Rogosin Institute</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ines Chicos</last_name>
      <email>inc9021@nyp.org</email>
    </contact>
    <investigator>
      <last_name>Daniel Cukor, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Durham VA Healthcare System</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jeanette Rutledge</last_name>
      <email>jeanette.rutledge@duke.edu</email>
    </contact>
    <investigator>
      <last_name>Patrick Pun, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VA Portland Healthcare System</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Adams</last_name>
      <email>Melissa.Adams1@va.gov</email>
    </contact>
    <investigator>
      <last_name>Benjamin Morasco, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Taylor Stallings</last_name>
      <email>taylor.stallings@pennmedicine.upenn.edu</email>
    </contact>
    <investigator>
      <last_name>Nwamaka Eneanya, MD, MPH</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Melissa Weimer</last_name>
      <email>weimermc@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Manisha Jhamb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sonya Williams</last_name>
      <email>sonya.l.williams@vumc.org</email>
    </contact>
    <investigator>
      <last_name>Kerri Cavanaugh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Washington</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lori Linke</last_name>
      <email>llinke@nephrology.washington.edu</email>
    </contact>
    <investigator>
      <last_name>Rajnish Mehrotra, MD, MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>West Virginia University</name>
      <address>
        <city>Morgantown</city>
        <state>West Virginia</state>
        <zip>26506</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheryl Dalton</last_name>
      <email>cldalton@hsc.wvu.edu</email>
    </contact>
    <investigator>
      <last_name>Bethany Pellegrino, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>September 15, 2020</study_first_submitted>
  <study_first_submitted_qc>September 25, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">October 1, 2020</study_first_posted>
  <last_update_submitted>July 27, 2021</last_update_submitted>
  <last_update_submitted_qc>July 27, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 29, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hemodialysis</keyword>
  <keyword>pain</keyword>
  <keyword>opioids</keyword>
  <keyword>pain coping skills</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Failure, Chronic</mesh_term>
    <mesh_term>Chronic Pain</mesh_term>
    <mesh_term>Opioid-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Buprenorphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified participant-level data will be transferred to the National Institute of Diabetes and Digestive and Kidney Diseases NIDDK) Central Repository after the trial has been completed.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_info_type>Analytic Code</ipd_info_type>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

